Greenberg Traurig is extremely proud to represent Redhill Biopharma with the recent announcement of providing an initial update on the compassionate use program with its investigational drug, opaganib, in patients with confirmed SARS-CoV-2 infection (COVID-19) in Israel.
RedHill Biopharma is a longstanding client of GT’s Barry Schindler, Chair of Greenberg Traurig’s Global Patent Prosecution Group, and an active member of the firm’s Israel Practice.
RedHill Biopharma, a biopharmaceutical company focused on gastrointestinal diseases, treated their first two patients with opaganib at a leading hospital in Israel. At the time of treatment initiation, both patients suffered from moderate to severe acute respiratory symptoms related to SARS-CoV-2 infection, required supplemental oxygenation and were hypoxic despite being treated with maximum flow of oxygen with cannulas.
Greenberg Traurig is committed to supporting the Israeli industry. Especially now, we work closely with local technology companies working on innovative solutions to the unique issues facing the global community during these critical times.
Greenberg Traurig takes pride in guiding start-ups, large multinational public companies, research organizations, and not-for-profit care providers, as well as investors, venture capital funds, and public agencies from discovery through commercialization and product marketing.
To view the full press release, please click here.